🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

RecruitingPhase 1, Phase 2Ages 50 Years - anyAllEyconis INC.
NCT07587515 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria * Willing and able to comply with clinic visits and study-related procedures * Provide signed informed consent Exclusion Criteria: * Known hypersensitivity or known allergy that would preclude study drug administration * Inability to obtain ophthalmic imaging, eg, due to media opacity, inadequate pupillary dilation, allergy to fluorescein dye or lack of venous access * Uncontrolled diabetes mellitus * History of cerebrovascular accident (CVA) or myocardial infarction within 180 days of the Day 1 visit * Renal failure, dialysis, or history of renal transplant * Concurrent psychiatric or medical condition that in the opinion of the Investigator will interfere with study participation or completion * Pregnant or breastfeeding women
💊

What it tests

  • EYC-0305
📍

Where

7 sites
Beverly Hills, CA
Beverly Hills, United States
Modesto, CA
Modesto, United States
Wake Forest, NC
Wake Forest, United States
Erie, PA
Erie, United States
Bellaire, TX
Bellaire, United States
McAllen, TX
McAllen, United States
The Woodlands, TX
The Woodlands, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy